Study #2020-1135
An open label, multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation
MD Anderson Study Status
Not Accepting
Treatment Agent
ABL001
Description
This study will be a multicenter Phase IIIb open-label, three-cohort study of asciminib in patients with CML-CP without T315I mutation who have had at least 2 prior TKIs and CML-CP harboring the T315I mutation with at least 1 prior TKI
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Chronic Myelogenous Leukemia - Chronic Phase
Study phase:
Phase III
Physician name:
Ghayas Issa
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.